Lemborexant

• Insomnia
• Sleep Onset Difficulties
• Sleep Maintenance Problems
• Sleep Disorders

Lemborexant is a dual orexin receptor antagonist (DORA) used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. This medication works by blocking wakefulness-promoting orexin neuropeptides, offering a different mechanism than traditional sleep aids.

Mechanism of Action

Lemborexant is a competitive antagonist of orexin receptors OX1R and OX2R, with approximately equal affinity for both receptor subtypes. Orexins (also called hypocretins) are neuropeptides produced by neurons in the lateral hypothalamus that promote and maintain wakefulness. By blocking the binding of wake-promoting orexin neuropeptides to their receptors, lemborexant suppresses the wake drive, allowing sleep to occur more naturally. This mechanism is distinct from GABAergic sleep aids and may result in a more physiological sleep pattern with less next-day impairment.

Available Formulations

Lemborexant is available as oral tablets in 5 mg and 10 mg strengths. The tablets should be taken immediately before going to bed, with at least 7 hours remaining before the planned time of waking. The tablets should not be taken with or soon after a meal, as this may delay the onset of effect.

Medical Uses

Lemborexant is FDA-approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Clinical trials demonstrated improvements in subjective sleep onset latency, wake after sleep onset, subjective total sleep time, and sleep quality compared to placebo. It may be particularly useful for patients who have not responded to other sleep medications or who experience significant next-day impairment with GABAergic agents.

Dosing Guidelines

The recommended dose is 5 mg taken immediately before going to bed, with at least 7 hours remaining before planned awakening. The dose may be increased to 10 mg based on clinical response and tolerability. The maximum recommended dose is 10 mg once per night. Taking lemborexant with or soon after a meal may delay the onset of effect. Time to effect may be longer if taken with food.

Important Safety Information

Lemborexant is a Schedule IV controlled substance due to potential for abuse. The medication can cause CNS depressant effects and daytime impairment; patients should be cautioned about driving or operating machinery. Complex sleep behaviors (sleep-walking, sleep-driving, engaging in activities while not fully awake) have been reported with sleep medications; discontinue if these occur. Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms may occur. Worsening of depression or suicidal ideation may occur; monitor patients with psychiatric illness.

Drug Interactions

Strong or moderate CYP3A inhibitors (itraconazole, clarithromycin, fluconazole) increase lemborexant exposure; maximum dose is 5 mg when combined with weak CYP3A inhibitors. Strong CYP3A inducers (rifampin) significantly decrease lemborexant exposure; avoid combination. CNS depressants (alcohol, other sleep medications, opioids, sedating antihistamines) may have additive CNS depressant effects.

Special Populations

There are no adequate data on lemborexant use during pregnancy. Animal studies showed adverse effects on embryo-fetal development at high doses. Use during pregnancy only if clearly needed. It is unknown whether lemborexant is excreted in human breast milk. Safety and efficacy have not been established in pediatric patients. Elderly patients do not require dose adjustment but may be more sensitive to effects. No dose adjustment is needed for renal impairment. Patients with moderate hepatic impairment should not exceed 5 mg; lemborexant is not recommended in severe hepatic impairment.